Active	0	6	O
hair	7	11	B-Multi-tissue_structure
growth	12	18	O
(	19	20	O
anagen	20	26	O
)	26	27	O
is	28	30	O
associated	31	41	O
with	42	46	O
angiogenesis	47	59	O
.	59	60	O

After	62	67	O
the	68	71	O
completion	72	82	O
of	83	85	O
skin	86	90	B-Organ
development	91	102	O
,	102	103	O
angiogenesis	104	116	O
,	116	117	O
i	118	119	O
.	119	120	O
e	120	121	O
.	121	122	O
,	122	123	O
the	124	127	O
growth	128	134	O
of	135	137	O
new	138	141	O
capillaries	142	153	B-Tissue
from	154	158	O
pre	159	162	O
-	162	163	O
existing	163	171	O
blood	172	177	B-Multi-tissue_structure
vessels	178	185	I-Multi-tissue_structure
,	185	186	O
is	187	189	O
held	190	194	O
to	195	197	O
occur	198	203	O
in	204	206	O
the	207	210	O
skin	211	215	B-Organ
only	216	220	O
under	221	226	O
pathologic	227	237	O
conditions	238	248	O
.	248	249	O

It	250	252	O
has	253	256	O
long	257	261	O
been	262	266	O
noted	267	272	O
,	272	273	O
however	274	281	O
,	281	282	O
that	283	287	O
hair	288	292	B-Multi-tissue_structure
follicle	293	301	I-Multi-tissue_structure
cycling	302	309	O
is	310	312	O
associated	313	323	O
with	324	328	O
prominent	329	338	O
changes	339	346	O
in	347	349	O
skin	350	354	B-Organ
perfusion	355	364	O
,	364	365	O
that	366	370	O
the	371	374	O
epithelial	375	385	B-Tissue
hair	386	390	I-Tissue
bulbs	391	396	I-Tissue
of	397	399	O
anagen	400	406	B-Multi-tissue_structure
follicles	407	416	I-Multi-tissue_structure
display	417	424	O
angiogenic	425	435	O
properties	436	446	O
,	446	447	O
and	448	451	O
that	452	456	O
the	457	460	O
follicular	461	471	B-Tissue
dermal	472	478	I-Tissue
papilla	479	486	I-Tissue
can	487	490	O
produce	491	498	O
angiogenic	499	509	O
factors	510	517	O
.	517	518	O

Despite	519	526	O
these	527	532	O
suggestive	533	543	O
observations	544	556	O
,	556	557	O
no	558	560	O
formal	561	567	O
proof	568	573	O
is	574	576	O
as	577	579	O
yet	580	583	O
available	584	593	O
for	594	597	O
the	598	601	O
concept	602	609	O
that	610	614	O
angiogenesis	615	627	O
is	628	630	O
a	631	632	O
physiologic	633	644	O
event	645	650	O
that	651	655	O
occurs	656	662	O
all	663	666	O
over	667	671	O
the	672	675	O
mature	676	682	O
mammalian	683	692	O
integument	693	703	O
whenever	704	712	O
hair	713	717	B-Multi-tissue_structure
follicles	718	727	I-Multi-tissue_structure
switch	728	734	O
from	735	739	O
resting	740	747	O
(	748	749	O
telogen	749	756	O
)	756	757	O
to	758	760	O
active	761	767	O
growth	768	774	O
(	775	776	O
anagen	776	782	O
)	782	783	O
.	783	784	O

This	785	789	O
study	790	795	O
uses	796	800	O
quantitative	801	813	O
histomorphometry	814	830	O
and	831	834	O
double	835	841	O
-	841	842	O
immunohistologic	842	858	O
detection	859	868	O
techniques	869	879	O
for	880	883	O
the	884	887	O
demarcation	888	899	O
of	900	902	O
proliferating	903	916	O
endothelial	917	928	B-Cell
cells	929	934	I-Cell
,	934	935	O
to	936	938	O
show	939	943	O
that	944	948	O
synchronized	949	961	O
hair	962	966	B-Multi-tissue_structure
follicle	967	975	I-Multi-tissue_structure
cycling	976	983	O
in	984	986	O
adolescent	987	997	O
C57BL	998	1003	B-Organism
/	1003	1004	I-Organism
6	1004	1005	I-Organism
mice	1006	1010	I-Organism
is	1011	1013	O
associated	1014	1024	O
with	1025	1029	O
substantial	1030	1041	O
angiogenesis	1042	1054	O
,	1054	1055	O
and	1056	1059	O
that	1060	1064	O
inhibiting	1065	1075	O
angiogenesis	1076	1088	O
in	1089	1091	O
vivo	1092	1096	O
by	1097	1099	O
the	1100	1103	O
intraperitoneal	1104	1119	O
application	1120	1131	O
of	1132	1134	O
a	1135	1136	O
fumagillin	1137	1147	B-Drug_or_compound
derivative	1148	1158	I-Drug_or_compound
retards	1159	1166	O
experimentally	1167	1181	O
induced	1182	1189	O
anagen	1190	1196	O
development	1197	1208	O
in	1209	1211	O
these	1212	1217	O
mice	1218	1222	B-Organism
.	1222	1223	O

Thus	1224	1228	O
,	1228	1229	O
angiogenesis	1230	1242	O
is	1243	1245	O
a	1246	1247	O
physiologic	1248	1259	O
event	1260	1265	O
in	1266	1268	O
normal	1269	1275	O
postnatal	1276	1285	O
murine	1286	1292	B-Organism
skin	1293	1297	B-Organ
,	1297	1298	O
apparently	1299	1309	O
is	1310	1312	O
dictated	1313	1321	O
by	1322	1324	O
the	1325	1328	O
hair	1329	1333	B-Multi-tissue_structure
follicle	1334	1342	I-Multi-tissue_structure
,	1342	1343	O
and	1344	1347	O
appears	1348	1355	O
to	1356	1358	O
be	1359	1361	O
required	1362	1370	O
for	1371	1374	O
normal	1375	1381	O
anagen	1382	1388	O
development	1389	1400	O
.	1400	1401	O

Anagen	1402	1408	O
-	1408	1409	O
associated	1409	1419	O
angiogenesis	1420	1432	O
offers	1433	1439	O
an	1440	1442	O
attractive	1443	1453	O
model	1454	1459	O
for	1460	1463	O
identifying	1464	1475	O
the	1476	1479	O
physiologic	1480	1491	O
controls	1492	1500	O
of	1501	1503	O
cutaneous	1504	1513	O
angiogenesis	1514	1526	O
,	1526	1527	O
and	1528	1531	O
an	1532	1534	O
interesting	1535	1546	O
system	1547	1553	O
for	1554	1557	O
screening	1558	1567	O
the	1568	1571	O
effects	1572	1579	O
of	1580	1582	O
potential	1583	1592	O
antiangiogenic	1593	1607	O
drugs	1608	1613	O
in	1614	1616	O
vivo	1617	1621	O
.	1621	1622	O

